Innovations in Exosome Therapeutics Session
Jul 08,2026
Exosomes are emerging as one of the most promising biotech frontiers after cell therapy. From large-scale manufacturing to CMC research, from engineering modification to clinical translation, from regulatory pathways to industrial ecosystem — the industrialization of innovative exosome drugs is reaching a critical inflection point from technical validation to value realization.
The "Innovative Exosome Drugs Session" brings together leading scientists, clinical experts, and industry pioneers in the exosome field. Deep discussions will focus on key topics including large-scale exosome manufacturing, CMC research and clinical translation, engineered exosome IND pathways, and exosome-driven regulatory innovation — presenting a comprehensive panoramic dialogue from bench to bedside, from technology to industry.
July 22–24, National Exhibition and Convention Center (Shanghai). We look forward to exploring the path to industrialization of innovative exosome drugs with you.
Conference Agenda
10:00–10:20 3D Intelligent Manufacturing Technology Empowers Large-Scale Manufacturing of Extracellular Vesicle Drugs
Xiaojun Yan: Co-founder & CTO, CytoNiche
10:20–10:35 CMC Research and Clinical Translation Challenges of Extracellular Vesicle Therapeutics
Hongwu Zhang: Chairman, Shanghai Stexo Biotechnology
10:35-10:50 R&D and Clinical Development of Engineered Exosomes for IND Pathway
Guoying Zhou: Founder, Chairman & CEO, ImmVira
10:50-11:05 The Era of Integrated Medicine Driven by Extracellular Vesicle Technology
Zhentao Li: CEO, Carrier Biomed (Suzhou)
11:05-11:20 Under Order No. 818: Regulatory Landscape and Innovation Pathways of Exosomes
Lei Zhang: CTO, Boyalife Stem Cell
11:20-12:00 Roundtable: Innovative Exosome Drugs from Lab to Clinic: What Are the Biggest Hurdles? (Large-Scale Manufacturing, Quality Standards, Regulatory Pathways, Investment Opportunities and Risks)
Jerry Liu（Moderator ）：Vice President, CoJourney; Chief Brand Officer, TONACEA
Wei Liu：Co-Founder & CEO, CytoNiche
Hongwu Zhang：Chairman, Shanghai Stexo Biotechnology
Lei Zhang：CTO, Boyalife Stem Cell
Haizi Cheng：Director of R&D, CMC in Charge, Obio Technology
Leo Xu：FE ZENITH CAPITAI Managing Director& Head of Healthcare Investment
Follow or Contact Us
Follow the TONACEA Official WeChat Account and scan the QR code to register. Stay updated with the latest conference news.
Public Account QR Code
Registration QR Code
Conference Service Hotline
© 2026 TONACEA (Shanghai) Technology Development Co., Ltd. All rights reserved. All rights reserved.
